Welcome to our dedicated page for Lunai Bioworks news (Ticker: LNAI), a resource for investors and traders seeking the latest updates and insights on Lunai Bioworks stock.
Lunai Bioworks Inc. (NASDAQ: LNAI) generates news at the intersection of AI-powered drug discovery, cancer immunotherapy, neurology, and biodefense. Company announcements and media coverage highlight its use of advanced machine learning, generative biology, and proprietary neurotoxicity datasets to advance therapeutic programs and security-focused research.
Recent news releases describe preclinical breakthroughs in allogeneic dendritic cell therapy for pancreatic cancer, where Lunai reports complete regression of primary and metastatic tumors in humanized mouse models using a second-generation clinical-compliant construct. The company has also announced a first letter of intent to license this immune cell therapy, peer-reviewed publications in journals such as Vaccines, and regulatory interactions supporting potential clinical translation.
Lunai-related news also covers its Augusta platform and the work of its subsidiary BioSymetrics in neurodegenerative and neuromuscular diseases. Updates include identification of Parkinson's disease subtypes and progression-linked targets using PPMI data, multimodal AI models for Alzheimer's disease diagnostics, and participation in a Nature Communications study on serum biomarkers in Duchenne muscular dystrophy. These stories emphasize biomarker discovery, precision stratification, and collaborations with academic and industry partners.
On the biodefense side, Lunai has issued news about AI and zebrafish-based platforms for detecting acetylcholinesterase-interacting compounds relevant to neurotoxicity and potential chemical threats. Corporate and capital markets updates, such as rebranding from Renovaro Inc. to Lunai Bioworks, adoption of the LNAI ticker, reverse stock split, Nasdaq compliance, and private placements, also appear in the news flow. Investors and observers can use this page to follow scientific milestones, partnership discussions, regulatory updates, and financing events related to Lunai Bioworks.
Lunai Bioworks (NASDAQ: LNAI) announced issuance of U.S. Patent No. 12,369,861 on Feb 19, 2026 for "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions."
The patent covers Lunai's foundational multimodal data standardization and bias-removal layer used before predictive AI modeling, intended to improve biomarker discovery, disease subtyping, and gene network mapping across CNS, oncology, and biodefense programs.
Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC Business Minute on Feb 13, 2026. CEO David Weinstein described the company’s proprietary AI platform for accelerating therapeutic discovery in CNS disorders and strengthening biodefense preparedness.
The platform integrates multimodal biological datasets, advanced machine learning, and in vivo validation to identify targets, optimize candidates, and compress development timelines. The company said it is advancing discussions with pharmaceutical firms and government agencies about its biotech and biodefense capabilities.
Lunai Bioworks (NASDAQ:LNAI) says its Augusta AI platform is now commercial after 12 months of development and is in active negotiations with pharmaceutical and drug‑discovery partners. The company highlights three revenue engines: AI drug discovery (CNS and new oncology pilot), AI biodefense programs targeting government contracts, and an allogeneic dendritic cell immunotherapy with published preclinical tumor regressions and an LOI for licensing.
The release emphasizes faster target validation via high‑throughput in vivo testing, near‑term pilots that can expand to commercial relationships, and ongoing efforts to finalize biodefense funding and a pharma royalty partnership.
Lunai Bioworks (NASDAQ: LNAI) launched an AI oncology pilot on Feb 9, 2026 to analyze randomized Phase 2 metastatic colorectal cancer trial data with a clinical-stage partner. The pilot uses Lunai's Augusta AI platform to evaluate de-identified patient-level clinical, imaging, and longitudinal outcomes focusing on overall survival and disease progression.
The goal is to define biologically meaningful patient subgroups to inform FDA trial design, optimized inclusion criteria, endpoint strategy, and statistical powering, with potential expansion to multi-study commercial programs and other tumor types if data support it.
Lunai Bioworks (NASDAQ: LNAI) launched Sentinel, a transformer-based AI safeguard that embeds inside large language and scientific foundation models to screen and block generation of novel chemical threat agents in real time. Sentinel combines Lunai's chemical foundation model trained on ~550 million public chemical structures and fine-tuned with the company's proprietary in-vivo toxicology and phenotypic datasets to detect latent toxic signatures and mechanisms, including neurotoxic and cytotoxic patterns. The product is positioned as part of a three-program biodefense strategy alongside Pathfinder and Counteract and targets AI developers, government agencies, and life-science platforms seeking integrated molecular-level biosecurity.
Lunai Bioworks (NASDAQ: LNAI) completed an NIH STTR commercial milestone creating high-resolution, multidimensional behavioral signatures of ethanol exposure and withdrawal and has launched a commercial Alcohol Use Disorder (AUD) drug-discovery program.
The program uses scalable high-throughput vertebrate screening, targets underexplored mechanisms, is supported by NIH funding, and is run in collaboration with Dr. Calum MacRae at Brigham and Women's Hospital/Harvard Medical School.
Company cites a large unmet need: ~30 million U.S. individuals affected, ~95% receiving no effective pharmacologic treatment, and a ~$250 billion annual economic cost.
Lunai Bioworks (NASDAQ: LNAI) was featured in International Business Times on Dec 17–18, 2025 for advancing AI-enabled drug discovery and active partnership discussions around multiple CNS programs, including Parkinson's, Alzheimer's and epilepsy.
The piece highlights Lunai's Augusta platform integrating longitudinal clinical data, large-scale proteomics and phenotypic analysis, use of PPMI Parkinson's data to identify patient subtypes and targets, and the company's focus on non-dilutive partnerships to extend runway and validate the platform.
Market context cited includes recent landmark AI-drug deals, an estimated $240 billion revenue-at-risk tailwind, ~$1.3 trillion capital for external innovation, ~11 million shares sold short vs a post-split float of ~23 million, and a 2025 market-cap reset from >$350M to < $30M.
Lunai Bioworks (NASDAQ: LNAI) announced identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets intended to accelerate proof-of-concept programs and strategic partnerships.
Analysis integrated longitudinal clinical and proteomic data from >650 participants and ~4,500 proteomic probes (median follow-up ≥2.5 years), linking subtypes to rapid progression, cognitive decline, and functional impairment. Lunai is initiating experimental validation, preclinical model development, and biomarker qualification while evaluating co-development opportunities in a market projected to exceed $13 billion by the 2030s.
Lunai Bioworks (NASDAQ: LNAI) announced it has secured a first letter of intent (LOI) to license its next‑generation dendritic cell combination therapy (DCCT) after peer‑reviewed publication and independent expert review. In humanized mouse models of pancreatic cancer, the DCCT produced complete regression of primary and metastatic tumors with no recurrence and 80–90% tumor size reduction across two studies. Lunai also reported a successful pre‑IND meeting with the FDA and plans for formal licensing negotiations and pre‑IND activities in early 2026 toward a proposed Phase I trial for high‑need solid tumors.
Lunai Bioworks (NASDAQ: LNAI) announced that a second‑generation, clinical‑grade dendritic cell (DC) therapy produced complete regression of primary and metastatic pancreatic tumors in preclinical humanized mouse models.
The Brief Report was published in Vaccines on Nov 2, 2025 and describes an optimized, clinically compliant construct that preserves the original product's efficacy while improving promoter and manufacturing elements to support IND‑enabling studies.
The therapy triggered robust activation of cytotoxic T cells and NK cells, and the company says the data advance partnering conversations and the platform's translation toward clinical development.